• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Rosacea - Pipeline Review, H2 2011 - Product Image

Rosacea - Pipeline Review, H2 2011

  • ID: 1943738
  • October 2011
  • 54 pages
  • Global Markets Direct

Rosacea - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Rosacea - Pipeline Review, H2 2011', provides an overview of the Rosacea therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea. 'Rosacea - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rosacea.
- A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rosacea Overview
Therapeutics Development
An Overview of Pipeline Products for Rosacea
Rosacea Therapeutics under Development by Companies
Rosacea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Rosacea Therapeutics - Products under Development by Companies
Rosacea Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Rosacea Therapeutics Development
Allergan, Inc.
Valeant Pharmaceuticals International
Paratek Pharmaceuticals, Inc.
Celgene Corporation
Helix BioMedix, Inc.
Paloma Pharmaceuticals, Inc.
Foamix Ltd.
Gene Signal International SA.
ELORAC, Inc.
Cutanea Life Sciences
Rosacea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CC-10004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HB1345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLS001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDP 115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clindamycin Phosphate + Tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcium Dobesilate + Pulsed Dye Laser - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FXFM244 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetracyclines For Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-0301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Palomid 529 Topical - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosacea Therapeutics – Drug Profile Updates
Rosacea Therapeutics - Discontinued Products
Rosacea - Featured News
Apr 19, 2011: Vicept Announces Positive Results From Second Phase II Study Of V-101 For Treatment Of Type I Rosacea
Jan 10, 2011: Vicept Reports Positive Phase II Data Of V-101 In Type I Rosacea
Nov 18, 2010: Elorac Announces Phase III Study Results Of Carbamide Peroxide For Treatment Of Acne And Rosacea
Aug 05, 2010: Vicept Therapeutics Announces Positive Clinical Study Results Of V-101 For The Treatment Of The Erythema Of Rosacea
May 31, 2010: Foamix To Present At The UBS 2010 Global Specialty Pharmaceuticals Conference
Oct 17, 2007: Cutanea Announces Promising Phase II Results In Rosacea With Omiganan Plans To Move Forward With Phase III.
Jul 09, 2007: Warner Chilcott and Paratek Pharmaceuticals Sign Collaboration Agreement For Novel, Narrow-Spectrum Agents For Acne And Rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos